These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7472005)

  • 1. [The characteristics of ovarian serous tumors of borderline malignancy (author's transl)].
    Tang MY
    Zhonghua Fu Chan Ke Za Zhi; 1980; 15(2):87-90. PubMed ID: 7472005
    [No Abstract]   [Full Text] [Related]  

  • 2. The characteristics of ovarian serous tumors of borderline malignancy.
    Tang MY; Lian LJ; Liu TH
    Chin Med J (Engl); 1980 Jul; 93(7):459-64. PubMed ID: 6772392
    [No Abstract]   [Full Text] [Related]  

  • 3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reversion of malignancy of immature ovarian teratoma (author's transl)].
    Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 1979; 14(4):267-71. PubMed ID: 555886
    [No Abstract]   [Full Text] [Related]  

  • 5. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
    Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
    Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
    Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
    Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
    Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.
    Vandenput I; Amant F; Vergote I
    Gynecol Oncol; 2005 Sep; 98(3):523; author reply 524-5. PubMed ID: 16054202
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cytophotometric study of papillary ovarian cystomas. Borderline cases of malignancy (author's transl)].
    Sachs H; Stegner HE; Würthner K
    Beitr Pathol; 1974 Jan; 151(1):42-64. PubMed ID: 4817524
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
    Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
    Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
    Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
    Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of borderline tumors of the ovary: state of the art.
    Tropé C; Kaern J
    Semin Oncol; 1998 Jun; 25(3):372-80. PubMed ID: 9633850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Causes of deaths of patients with ovarian carcinoma (author's transl)].
    Krafft W; Behling H; Preibsch W; Brückmann D; Schirmer A
    Zentralbl Gynakol; 1981; 103(5):261-6. PubMed ID: 7223171
    [No Abstract]   [Full Text] [Related]  

  • 20. Borderline tumors of the ovary and peritoneal implants.
    Denkert C; Dietel M
    Verh Dtsch Ges Pathol; 2005; 89():84-91. PubMed ID: 18035677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.